Short answer
ENANTA PHARMACEUTICALS INC (ENTA) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 8.01 (Other Events). UPC invalidated Enanta’s EP 4 051 265 patent covering Pfizer’s Paxlovid activities.
ENANTA PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- UPC invalidated Enanta’s EP 4 051 265 patent covering Pfizer’s Paxlovid activities
- Infringement claims against Pfizer were dismissed as unfounded across 18 participating EU member states
- Decision removes this litigation pathway for potential Paxlovid-related remedies or licensing value
- Pfizer’s counterclaim succeeded, weakening Enanta’s intellectual-property position in Europe
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ENANTA PHARMACEUTICALS INC 8-K filings
Get the next ENTA 8-K as it lands
Follow ENTA for push alerts, or ask the research agent what this filing means.